1. Market Research
  2. > Pharmaceutical Market Trends
  3. > France Pharmaceuticals and Healthcare Report Q4 2016

France Pharmaceuticals and Healthcare Report Q4 2016

  • September 2016
  • -
  • Business Monitor International
  • -
  • 115 pages

Includes 3 FREE quarterly updates

BMI View:

The UK vote to leave the EU will weigh on France's economic growth over the next few quarters, which in turn will pose downside risks to our pharmaceutical and healthcare sector forecasts. Despite the large pharmaceutical market and high drug spending per capita, which will continue to make France a major global market for drugmakers, market expansion will only resume at a slow pace over the next few years, with return to marginal positive growth in 2017. In line with our view in recent quarters, the rate of investment growth in France's pharmaceutical sector has remained relatively subdued in H116, while this trend will likely continue over the coming quarters, in part due to sluggish labour market reform.

Headline Expenditure Projections


- Pharmaceuticals: EUR33.46bn (USD37.11bn) in 2015 to EUR33.34bn (USD35.68bn) in 2016; -0.3% in local currency terms and -3.9% in US dollar terms. Forecast broadly in line with last quarter.

- Healthcare: EUR251.26bn (USD278.66bn) in 2015 to EUR257.25bn (USD275.26bn) in 2016; +2.4% in local currency terms and -1.2% in US dollar terms. Forecast revised downwards from last quarter.

Table Of Contents

France Pharmaceuticals and Healthcare Report Q4 2016
BMI Industry View 7
Table: Headline Pharmaceuticals and Healthcare Forecasts (France 2014-2020) 7
SWOT 9
Industry Forecast 11
Pharmaceutical Market Forecast 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (France 2012-2020) 14
Healthcare Market Forecast 15
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (France 2012-2020) 18
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (France 2012-2020) 19
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (France 2012-2020) 19
Prescription Drug Market Forecast 20
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (France 2012-2020) 21
Patented Drug Market Forecast 22
Table: Patented Drug Market Indicators, Historical Data And Forecasts (France 2012-2020) 23
Generic Drug Market Forecast 24
Table: Generic Drug Market Indicators, Historical Data And Forecasts (France 2012-2020) 26
OTC Medicine Market Forecast 27
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (France 2012-2020) 29
Pharmaceutical Trade Forecast 30
Table: Pharmaceutical Trade Data And Forecasts (France 2014-2020) 32
Table: Pharmaceutical Trade Data And Forecasts local currency (France 2014-2020) 32
Industry Risk/Reward Index 33
Western Europe Risk/Reward Index 33
France Risk/Reward Index 39
Rewards 39
Risks 39
Regulatory Review 41
Intellectual Property Issues 43
Pricing and Reimbursement Regime 44
Table: France Reimbursement Categories 45
Market Overview 55
Healthcare Sector 56
Table: Projected Regional Ranking Of Physicians, 2017 62
Table: Healthcare Personnel (France 2010-2015) 63
Table: Healthcare Activity (France 2010-2015) 63
Table: Healthcare Resources (France 2010-2015) 64
Research and Development 64
Clinical Trials 68
Epidemiology 70
Competitive Landscape 72
Research-Based Industry 72
Table: Table: Multinational Market Activity 74
Generic Drugmakers 76
Pharmaceutical Distribution 76
Pharmaceutical Retail Sector 77
Company Profile 79
GlaxoSmithKline 79
Ipsen 82
Merck and Co 86
Novartis 89
Sanofi 92
Servier 100
Demographic Forecast 104
Table: Population Headline Indicators (France 1990-2025) 105
Table: Key Population Ratios (France 1990-2025) 105
Table: Urban/Rural Population and Life Expectancy (France 1990-2025) 106
Table: Population By Age Group (France 1990-2025) 106
Table: Population By Age Group % (France 1990-2025) 107
Glossary 109
Methodology 111
Pharmaceutical Expenditure Forecast Model 111
Healthcare Expenditure Forecast Model 111
Notes On Methodology 112
Risk/Reward Index Methodology 113
Index Overview 114
Table: Pharmaceutical Risk/Reward Index Indicators 114
Indicator Weightings 115

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Prostate Cancer Pricing, Reimbursement, and Access

Prostate Cancer Pricing, Reimbursement, and Access

  • $ 7 500
  • Industry report
  • July 2016
  • by Datamonitor Healthcare

Novel antiandrogens will need to present risk-sharing agreements in EU markets, while discussing contracting with US payers to ensure a competitive advantage. Vaccines suffer from inconclusive response ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7 000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

IMS World Review Executive™ 2016

IMS World Review Executive™ 2016

  • $ 6 860
  • Industry report
  • July 2016
  • by IMS Health

IMS World Review ExecutiveTM 2016 provides essential insights into worldwide sales of the pharmaceutical market, interlocking market trends and sales analysis from 2011 to 2015, including the breakdown ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.